metformin + roflumilast

This drug is a combination of two pharmaceutical agents, metformin and roflumilast, used together for their complementary therapeutic effects. - **Metformin** is a biguanide antihyperglycemic agent primarily indicated to improve glycemic control in type 2 diabetes mellitus by decreasing hepatic glucose production and increasing insulin sensitivity. It is commonly used alongside diet and exercise. - **Roflumilast** is a selective phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by increasing intracellular cyclic AMP levels in immune and structural cells. It is indicated to decrease the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) and also treats certain skin conditions such as plaque psoriasis. The combination leverages metformin’s glucose-lowering effects with roflumilast’s anti-inflammatory properties, potentially useful in patients who have comorbid metabolic dysfunction and inflammatory respiratory or dermatologic conditions.

Other names

metformin + roflumilast